Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2013
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary) ; Yttrium-90
- Indications Cancer metastases; Liver cancer
- Focus Adverse reactions
- 24 Oct 2012 Planned number of patients changed from 68 to 136 as reported by ClinicalTrials.gov.
- 24 Oct 2012 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov.
- 24 Oct 2012 Planned initiation date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.